Literature DB >> 12417380

Apolipoprotein E epsilon 4 allele frequency in demented and cognitively impaired patients with and without cerebrovascular disease.

Latchezar Traykov1, Anne-Sophie Rigaud, Sophie Baudic, Alain Smagghe, François Boller, Françoise Forette.   

Abstract

Controversy exists regarding the apolipoprotein E (ApoE) epsilon 4 allele association with vascular dementia (VaD). The results range from increased epsilon 4 frequency, similar to that found for Alzheimer's disease (AD), to no association at all. Our objective was to clarify the relationship between ApoE epsilon 4 allele and cerebrovascular disease (CVD) in demented and cognitively impaired patients. We examined the ApoE phenotypes in a sample of 452 subjects: 219 with AD, 45 with VaD, 62 with mixed dementia (MD), 45 with mild cognitive impairment (MCI) without CVD, 27 in which vascular disease was the most probable cause of cognitive decline (vascular mild cognitive impairment, VMCI) and 54 normal controls (NC). The study of the epsilon 4 allele frequency showed significant differences between: AD group and the VaD, VMCI and NC groups; MCI group compared with VMCI and NC groups; and MD group versus the VaD and NC groups (p<0.05-0.0001). The frequency of the epsilon 4 allele in the VaD and VMCI groups did not differ significantly from NC. In contrast to other studies, we did not detect a relationship between ApoE epsilon 4 allele and clinically diagnosed VaD. Our results also show that the epsilon 4 allele is not associated with cognitive impairment of vascular origin. In addition, we have confirmed that the ApoE epsilon 4 allele occurs frequently in late-onset AD and we have found similar association in cognitively impaired individuals without clinical CVD. These findings should contribute to the assessment of dementia risk profile in the elderly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417380     DOI: 10.1016/s0022-510x(02)00287-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive impairment-related mitochondrial dysfunction.

Authors:  Xueqi Gan; Long Wu; Shengbin Huang; Changjia Zhong; Honglian Shi; Guangyue Li; Haiyang Yu; Russell Howard Swerdlow; John Xi Chen; Shirley ShiDu Yan
Journal:  Free Radic Biol Med       Date:  2014-07-23       Impact factor: 7.376

2.  APOE ε2 and ε4 influence the susceptibility for Alzheimer's disease but not other dementias.

Authors:  Carlo Lovati; Daniela Galimberti; Diego Albani; Pierluigi Bertora; Eliana Venturelli; Giuliana Cislaghi; Ilaria Guidi; Chiara Fenoglio; Francesca Cortini; Francesca Clerici; Dario Finazzi; Gianluigi Forloni; Elio Scarpini; Claudio Mariani
Journal:  Int J Mol Epidemiol Genet       Date:  2010-04-05

Review 3.  Poststroke dementia in the elderly.

Authors:  Marie-Anne Mackowiak-Cordoliani; Stéphanie Bombois; Armelle Memin; Hilde Hénon; Florence Pasquier
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias.

Authors:  Mark Yarchoan; Sharon X Xie; Mitchel A Kling; Jon B Toledo; David A Wolk; Edward B Lee; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Steven E Arnold
Journal:  Brain       Date:  2012-11-30       Impact factor: 13.501

5.  The apolipoprotein E genotype predicts longitudinal transitions to mild cognitive impairment but not to Alzheimer's dementia: findings from a nationally representative study.

Authors:  C J Brainerd; V F Reyna; R C Petersen; G E Smith; A E Kenney; C J Gross; E S Taub; B L Plassman; G G Fisher
Journal:  Neuropsychology       Date:  2013-01       Impact factor: 3.295

6.  Mild cognitive impairment: historical development and summary of research.

Authors:  James Golomb; Alan Kluger; Steven H Ferris
Journal:  Dialogues Clin Neurosci       Date:  2004-12       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.